Moderna公司(MRNA)今日盘前股价大涨7.6%,主要原因是该公司公布的第三季度财报显示出人意料的盈利。
季报数据显示,Moderna公司第三季度实现盈利1300万美元,合每股3美分,远高于分析师此前预期的7.53亿美元亏损。Moderna公司COVID-19疫苗Spikevax在美国市场的销售额为18亿美元,同比增长3.5%,高于分析师预期的13.8亿美元。该公司表示,这主要得益于今年较早推出了COVID疫苗更新版本,确保了医疗机构的供应。
虽然公司的新型合胞病毒(RSV)疫苗销售额较低,仅1000万美元,大幅低于分析师预期的1.35亿美元。但整体而言,Moderna公司削减了大约50%的季度支出,部分原因是闲置产能和库存减少。公司重申今年的销售目标在30亿至35亿美元区间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.